PIANO

CompletedPhase NA

Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function - the PIANO Study

Lead sponsor

University Hospital, Basel, Switzerland

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Healthy volunteers

Eligibility highlights

•BMI 18.5-30•Male•Healthy volunteers

Primary endpoint

•Serum cortisol after Rybelsus

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06608433

Org study IDEKNZ2024-01744

Timeline

Milestones

Study first posted2024-09-23actual

Study start2025-01-16actual

Primary completion2025-10-31actual

Study completion2025-11-30actual

Last update posted2026-02-11actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age18 Years

Maximum age60 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

•Healthy male volunteers aged 18-60 years

•BMI 18.5-30 kg/m2

•No regular medication

Exclusion criteria

•participation in a trial with investigational drugs within 30 days

•vigorous physical exercise within 24 hours before the study participation

•alcohol intake within 24 hours before the study participation

•a history of intake of glucocorticoids or GLP-1 RA within the last 8 weeks.

•Known allergy towards GLP-1 RA

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Change in serum cortisol after Rybelsus vs. Placebo

Time frame:within 210 minutes after the intake of the study drug

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.